If you are one of those, see below for resources from the Ehlers Danlos Society
One payer commented that insurers view GLP-1 drugs as having high upfront costs with uncertain long-term effects, especially on obesity outcomes ( [21] )
But as standalone treatments, both tirzepatide and liraglutide carry minimal hypoglycemia risk, which is a major advantage over older diabetes drug classes
[DOI] [PubMed] [Google Scholar] Vahl T
Lanzinger S, Laubner K, Warncke K et al (2024) Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: insights from the multicenter real-world DPV registry
However, in both models, cancer cell growth was rescued under cystine-free with GSH-supplemented conditions (Extended Data Fig